Autonomix Medical(US:AMIX) Globenewswireยท2025-10-09 12:45Core Insights - Autonomix Medical, Inc. has received a new patent that enhances its position in a multi-billion-dollar market for nerve-targeted treatments, particularly in cardiology and related fields [1][2][3] Intellectual Property Development - The company has over 120 issued and pending patent applications, indicating a strong commitment to building a comprehensive global intellectual property portfolio in nerve-sensing and modulation [1] - The newly issued U.S. Patent No. 12,369,852 covers systems and methods for sensing autonomic signals and delivering precise cardiac therapies [1][3] Market Opportunity - The patent positions Autonomix to capitalize on high-growth areas in cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - The technology aims to provide precision therapies that could reduce the reliance on systemic beta-blockers, which often have undesirable side effects [2][3] Technological Advancements - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The platform has the potential to address various indications across multiple therapeutic areas, including cardiology, hypertension, and chronic pain management [4][6] Initial Focus and Future Potential - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain [6] - The investigational nature of the technology indicates that it has not yet received marketing clearance in the United States, suggesting ongoing development and potential future applications [6]